Table 1 Patient characteristics.
All patients N = 110 | Patients with C-SRT n = 28 | Patients with 18F-rhPSMA-7/18F-flotufolastat-guided SRT n = 82 | p | |
|---|---|---|---|---|
Age, years | ||||
Median | 72.0 | 69.5 | 73.0 | 0.126 |
Range | 50–84 | 57–79 | 50–84 | |
Treatment Fields, n (%) | ||||
PB | 25 (23%) | 25 (89%) | – | < 0.001* |
PB + ePLN | 3 (2.7%) | 3 (11%) | – | |
PB/SIB | 52 (47%) | – | 52 (63%) | |
PB/SIB + ePLN | 9 (8.2%) | – | 9 (11%) | |
PB + ePLN/SIB | 7 (6.4%) | – | 7 (8.5%) | |
PB/SIB + ePLN/SIB | 9 (8.2%) | – | 9 (11%) | |
ePLN/SIB | 5 (4.5%) | – | 5 (6.1%) | |
Postoperative Tumor Classification, n (%) | ||||
pT2a | 9 (8.2%) | 4 (14%) | 5 (6.1%) | 0.645 |
pT2b | 4 (3.6%) | 1 (3.6%) | 3 (3.7%) | |
pT2c | 43 (39%) | 8 (29%) | 35 (43%) | |
pT3 | 1 (0.9%) | 0 (0.0%) | 1 (1.2%) | |
pT3a | 30 (27%) | 9 (32%) | 21 (26%) | |
pT3b | 21 (19%) | 6 (21%) | 15 (18%) | |
Missing | 2 (1.8%) | 0 (0.0%) | 2 (2.4%) | |
Postoperative Nodal Status, n (%) | ||||
Negative (pN0) | 95 (86%) | 24 (86%) | 71 (87%) | 0.720 |
Positive (pN1) | 11 (10%) | 3 (11%) | 8 (9.8%) | |
Unknown (pNx) | 2 (1.8%) | 1 (3.6%) | 1 (1.2%) | |
Missing | 2 (1.8%) | 0 (0.0%) | 2 (2.4%) | |
Postoperative Surgical Margin, n (%) | ||||
Negative (R0) | 76 (69%) | 17 (61%) | 59 (72%) | 0.446 |
Positive (R1) | 23 (21%) | 7 (25%) | 16 (20%) | |
Unknown (Rx) | 6 (5.5%) | 3 (11%) | 3 (3.7%) | |
Missing | 5 (4.5%) | 1 (3.6%) | 4 (4.9%) | |
ISUP Grade Group, n (%) | ||||
1 (≤ 6) | 10 (9.1%) | 3 (11%) | 7 (8.5%) | 0.116 |
2 (3 + 4 = 7) | 37 (34%) | 9 (32%) | 28 (34%) | |
3 (4 + 3 = 7) | 36 (33%) | 5 (18%) | 31 (38%) | |
4 (8) | 9 (8.2%) | 3 (11%) | 6 (7.3%) | |
5 (9–10) | 14 (13%) | 7 (25%) | 7 (8.5%) | |
Missing | 4 (3.6%) | 1 (3.6%) | 3 (3.7%) | |
PSA before RT, ng/mL | ||||
Median | 0.39 | 0.32 | 0.45 | 0.029* |
Range | 0.20–22.00 | 0.20–3.97 | 0.20–22.00 | |
Additive ADT | ||||
Yes | 75 (68%) | 23 (82%) | 52 (63%) | 0.066 |
No | 35 (32%) | 5 (18%) | 30 (37%) | |
